

REMARKS

Claims 1-38 are pending in this application. New claims 39-40 have been added to identify the first substance as a biomolecule. Support for these claims may be found, for example, in the specification on page 1, line 22 to page 2, line 5. No new matter has been added.

The Examiner has required restriction of the claims as follows:

Group 1 – Claims 1-32 drawn to a biochip;

Group 2 – Claims 33-38 drawn to a method of fluid transfer in a biochip.

Applicant elects to prosecute the claims of Group 1 (claims 1-32), and has canceled the claims of Group 2 (claim 33-38) without prejudice to prosecuting these claims in a continuing application.

The Examiner has further required election of a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The Examiner indicated that claims 1-13 and 24-38 are generic. Applicant elects to prosecute the First Species, claims 14-21.

Should any issue remain to be resolved regarding the restriction/election requirements, Applicant requests that the Examiner telephone the undersigned attorney of record.

Dated: August 26, 2008

Respectfully submitted,

Customer No. 44702
OSTRAGER CHONG FLAHERTY
& BROITMAN P.C.

By: /joshua s. broitman/
Joshua S. Broitman
Reg. No. 38,006

570 Lexington Avenue
New York, New York 10022-6894
(212) 681-0600
Attorneys for Applicant